Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dale N Gerding

Showing results (141-150 of 199) with videos related to

Pageof 20
Sort By:
BMC Infectious Diseases|March 13, 2022
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trialRobert Orenstein, Erik R Dubberke, Sahil Khanna, et al.
Vaccine|December 18, 2020
Identification of patients at risk of Clostridioides difficile infection for enrollment in vaccine clinical trialsVanessa W Stevens, Ellyn M Russo, Yinong Young-Xu, et al.
Nature|March 3, 2009
Toxin B is essential for virulence of Clostridium difficileDena Lyras, Jennifer R O'Connor, Pauline M Howarth, et al.
JAMA|May 6, 2015
Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trialDale N Gerding, Thomas Meyer, Christine Lee, et al.
Infection Control and Hospital Epidemiology|May 7, 2014
Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 UpdateErik R Dubberke, Philip Carling, Ruth Carrico, et al.
The New England Journal of Medicine|January 22, 2010
Treatment with monoclonal antibodies against Clostridium difficile toxinsIsrael Lowy, Deborah C Molrine, Brett A Leav, et al.
Infection Control and Hospital Epidemiology|November 8, 2014
Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 updateErik R Dubberke, Philip Carling, Ruth Carrico, et al.
Journal of Clinical Microbiology|July 24, 2015
Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in StoolLinan Song, Mingwei Zhao, David C Duffy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 1, 2013
Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infectionCarolyn V Gould, Jonathan R Edwards, Jessica Cohen, et al.
The Lancet. Infectious Diseases|May 3, 2017
Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority studyRichard J Vickers, Glenn S Tillotson, Richard Nathan, et al.
Pageof 20

Showing results (141-150 of 199) with videos related to

Sort By:
Pageof 20
BMC Infectious Diseases|March 13, 2022
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trialRobert Orenstein, Erik R Dubberke, Sahil Khanna, et al.
Vaccine|December 18, 2020
Identification of patients at risk of Clostridioides difficile infection for enrollment in vaccine clinical trialsVanessa W Stevens, Ellyn M Russo, Yinong Young-Xu, et al.
Nature|March 3, 2009
Toxin B is essential for virulence of Clostridium difficileDena Lyras, Jennifer R O'Connor, Pauline M Howarth, et al.
JAMA|May 6, 2015
Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trialDale N Gerding, Thomas Meyer, Christine Lee, et al.
Infection Control and Hospital Epidemiology|May 7, 2014
Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 UpdateErik R Dubberke, Philip Carling, Ruth Carrico, et al.
The New England Journal of Medicine|January 22, 2010
Treatment with monoclonal antibodies against Clostridium difficile toxinsIsrael Lowy, Deborah C Molrine, Brett A Leav, et al.
Infection Control and Hospital Epidemiology|November 8, 2014
Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 updateErik R Dubberke, Philip Carling, Ruth Carrico, et al.
Journal of Clinical Microbiology|July 24, 2015
Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in StoolLinan Song, Mingwei Zhao, David C Duffy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 1, 2013
Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infectionCarolyn V Gould, Jonathan R Edwards, Jessica Cohen, et al.
The Lancet. Infectious Diseases|May 3, 2017
Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority studyRichard J Vickers, Glenn S Tillotson, Richard Nathan, et al.
Pageof 20